Katya

Ethinylestradiol, the active ingredient in Katya, is a combined oral contraceptive presented as a tablet for oral use. Together with gestodene, it provides estrogen and progestin activity that prevents pregnancy by inhibiting ovulation and altering cervical mucus in women of reproductive age.

GNH USA supplies Katya as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable logistics for global distribution, with dedicated support for procurement teams, and timely communication throughout the supply chain.

Katya, a combined oral contraceptive, acts on the hormonal regulation of the menstrual cycle to prevent pregnancy.

Contraception: prevents pregnancy by inhibiting ovulation and modifying cervical mucus. Menstrual cycle regulation: helps achieve more regular periods and reduces cycle length variability. Dysmenorrhea management: lessens menstrual pain through hormonal stabilization. Acne improvement: may reduce acne associated with androgen excess in women.

Katya may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type headaches. - Breast tenderness: swelling or discomfort. - Irregular bleeding: spotting between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Hypertensive crisis: sudden high blood pressure episodes. - Liver dysfunction: jaundice or abnormal liver enzymes.

Before prescribing Katya, clinicians should evaluate the following safety considerations.

Medical history assessment: screen for thromboembolic disorders, cardiovascular disease, liver disease, or hormone‑sensitive cancers. Smoking status: avoid use in women over 35 who smoke heavily. Drug interactions: review concomitant medications that may affect clotting risk or hormone metabolism. Pregnancy and lactation: contraindicated during pregnancy; advise effective contraception if breastfeeding. Store below 25°C: keep in the original pack, protect from moisture and light.

Katya can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Combined hormonal contraceptives with other estrogen‑containing products: increased risk of thromboembolism. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may reduce contraceptive effectiveness. - Antifungal agents (e.g., ketoconazole): can increase hormone levels, raising side‑effect risk.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., carbamazepine, phenytoin): may lower plasma concentrations, decreasing efficacy. - Rifampicin and other enzyme inducers: may reduce hormonal levels, risking breakthrough bleeding. - St. John’s wort: may diminish contraceptive effect.